+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Lonza Group Ltd (LONN) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 73 Pages
  • June 2024
  • GlobalData
  • Lonza Group AG
  • ID: 1291970
Lonza Group Ltd (LONN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Lonza Group Ltd (Lonza) is a contract manufacturing and development solutions company. It offers services including commercial mammalian and microbial manufacturing, clinical development, and manufacturing. The company also offers active pharmaceutical ingredients, cell and gene therapy capabilities, advanced intermediates, oral drug product development services, cell-culture modeling, genome editing, endotoxin products, and research media and testing products. Lonza provides solutions for health and well-being, microbial and hygiene control, and composites and material protection. It serves biotechnology, pharmaceutical, academic, and government research industries; manufacturers of health and consumer products; formulators and service companies. The company operates manufacturing and R&D facilities in Asia, Europe, and the Americas. Lonza is headquartered in Basel, Switzerland.

Lonza Group Ltd Key Recent Developments

  • May 14, 2024: Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024
  • Apr 02, 2024: Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
  • Mar 04, 2024: Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports
  • Jan 26, 2024: Lonza Group Announces Jean-Marc Huet to succeed Albert M. Baehny as Chairman of Lonza

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Lonza Group Ltd - Key Facts
  • Lonza Group Ltd - Key Employees
  • Lonza Group Ltd - Key Employee Biographies
  • Lonza Group Ltd - Major Products and Services
  • Lonza Group Ltd - History
  • Lonza Group Ltd - Company Statement
  • Lonza Group Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Lonza Group Ltd - Business Description
  • Business Segment: Biologics
  • Overview
  • Performance
  • Key Stats
  • Business Segment: Capsules and Health Ingredients
  • Overview
  • Performance
  • Key Stats
  • Business Segment: Cell & Gene
  • Overview
  • Performance
  • Key Stats
  • Business Segment: Small Molecules
  • Overview
  • Performance
  • Key Stats
  • Geographical Segment: Asia
  • Performance
  • Geographical Segment: Australia & New Zealand
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Latin America
  • Performance
  • Geographical Segment: North and Central America
  • Performance
  • Geographical Segment: Other Countries
  • Performance
  • R&D Overview
  • Lonza Group Ltd - Corporate Strategy
  • Lonza Group Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Lonza Group Ltd - Strengths
  • Lonza Group Ltd - Weaknesses
  • Lonza Group Ltd - Opportunities
  • Lonza Group Ltd - Threats
  • Lonza Group Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Lonza Group Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 14, 2024: Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024
  • Apr 02, 2024: Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
  • Mar 04, 2024: Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports
  • Jan 26, 2024: Lonza Group Announces Jean-Marc Huet to succeed Albert M. Baehny as Chairman of Lonza
  • Jan 26, 2024: Lonza Delivers Solid 2023 Performance with 10.9% CER Sales Growth and 29.8% CORE EBITDA Margin
  • Jan 26, 2024: Jean-Marc Huet to succeed Albert M. Baehny as Chairman of Lonza
  • Jan 17, 2024: Envision Energy Announces Collaboration with Five Global Healthcare Leaders to Unlock Renewable Energy in Davos
  • Jan 16, 2024: Five Global Healthcare Leaders Secure Industry-first, Multi-party Agreement to Access Renewable Power in China
  • Oct 16, 2023: Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
  • Oct 13, 2023: Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Lonza Group Ltd, Key Facts
  • Lonza Group Ltd, Key Employees
  • Lonza Group Ltd, Key Employee Biographies
  • Lonza Group Ltd, Major Products and Services
  • Lonza Group Ltd, History
  • Lonza Group Ltd, Other Locations
  • Lonza Group Ltd, Subsidiaries
  • Lonza Group Ltd, Joint Venture
  • Lonza Group Ltd, Key Competitors
  • Lonza Group Ltd, Ratios based on current share price
  • Lonza Group Ltd, Annual Ratios
  • Lonza Group Ltd, Interim Ratios
  • Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Lonza Group Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Lonza Group Ltd, Performance Chart (2019 - 2023)
  • Lonza Group Ltd, Ratio Charts
  • Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Teva Pharmaceutical Industries Ltd
  • H. Lundbeck AS
  • Merck KGaA
  • Eurofins Scientific SE
  • Sartorius AG
  • Sannitree International
  • Reckitt Benckiser Group Plc
  • Qiagen NV
  • Sonova Holding AG
  • Smith & Nephew Plc
  • Ipsen SA
  • Hikma Pharmaceuticals Plc
  • Alcon Inc
  • UCB SA
  • ICON Plc
  • Grifols SA